Results 41 to 50 of about 4,575,423 (299)

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham   +21 more
wiley   +1 more source

Resumption of Employment after Cervical Cancer Surgery: a 3-Year Follow-Up Study of Long-term Outcomes [PDF]

open access: yesВестник восстановительной медицины
INTRODUCTION. Despite advancements in cervical cancer (CC) diagnosis and treatment, surgical intervention remains the cornerstone of radical treatment. However, surgical procedures can result in complications such as lymphedema, sexual dysfunction, and ...
Dmitry V. Blinov   +8 more
doaj   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

open access: yesMolecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg   +43 more
wiley   +1 more source

Meaning over Miles: The predictive role of meaning of work in remote work frequency over time

open access: yesSocial Sciences and Humanities Open
As organizations navigate post-pandemic return-to-office (RTO) policies, understanding the psychological factors that drive employee preferences for remote and hybrid work is crucial.
Jaroslaw Grobelny, Agnieszka Springer
doaj   +1 more source

Primary care management of mild cognitive impairment in a stroke survivor: A case report on facilitating return to work [PDF]

open access: yesMalaysian Family Physician
This case report delves into facilitating return to work (RTW) in a working-age stroke survivor. The patient was a 42-year-old Malay man who experienced multifocal lacunar infarctions in April 2022.He demonstrated substantial motor function recovery but ...
Afiza Hanun Ahmad @ Hamid   +3 more
doaj   +1 more source

Occupational burn injuries in Finland 2011–2015

open access: yesInjury Epidemiology, 2022
Background This study comprises all hospitalized work-related burn injuries in one country during 2011–2015. The purpose was to describe demographics, causes and risk factors of occupational burn injuries with special focus on the outcome of return to ...
Lotta Purola, Heli Kavola, Jyrki Vuola
doaj   +1 more source

Crucial parameters for precise copy number variation detection in formalin‐fixed paraffin‐embedded solid cancer samples

open access: yesMolecular Oncology, EarlyView.
This study shows that copy number variations (CNVs) can be reliably detected in formalin‐fixed paraffin‐embedded (FFPE) solid cancer samples using ultra‐low‐pass whole‐genome sequencing, provided that key (pre)‐analytical parameters are optimized.
Hanne Goris   +10 more
wiley   +1 more source

Psychological morbidity and return to work after injury: multicentre cohort study [PDF]

open access: yes, 2017
Background: The benefits of work for physical, psychological and financial wellbeing are well documented. Return to work (RTW) after unintentional injury is often delayed, and psychological morbidity may contribute to this delay.
Ash   +29 more
core   +6 more sources

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

open access: yesMolecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy